Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in New York, specializing in the development of psychedelic-derived therapeutics for psychiatric and neurological disorders. Formerly known as MindMed, it focuses on creating scientifically rigorous treatments that target root causes, such as generalized anxiety disorder (GAD), major depressive disorder (MDD), and autism spectrum disorder (ASD), aiming for long-term remission over symptom management. The company's lead candidate, DT120 orally disintegrating tablet (ODT), a proprietary lysergide (LSD) D-tartrate formulation, has FDA Breakthrough Therapy Designation for GAD and is advancing through multiple Phase 3 trials, with topline data anticipated in 2026. Additional pipeline assets include DT402, the R-enantiomer of MDMA, under investigation for ASD to improve social communication via serotonergic mechanisms. Operating in the biotechnology sector of healthcare, Definium Therapeutics employs 74 people and drives innovation in psychoplastogenic drug development to address the mental health crisis. Founded around 2019, it exemplifies precision science applied to psychedelics for scalable healing.